Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

Chaurasia B, Tippetts TS,Mayoral Monibas R,Liu J,Li Y,Wang L, Wilkerson JL,Sweeney CR, Pereira RF,Sumida DH,Maschek JA, Cox JE,Kaddai V, Lancaster GI, Siddique MM,Poss A,Pearson M,Satapati S,Zhou H, McLaren DG, Previs SF,Chen Y,Qian Y,Petrov A,Wu M,Shen X,Yao J, Nunes CN, Howard AD, Wang L, Erion MD,Rutter J, Holland WL, Kelley DE, Summers SA

Yearbook of Paediatric Endocrinology（2020）

Cited 236|Views88

No score

Abstract

By genetically engineering mice, the authors deleted the enzyme dihydroceramide desaturase 1 (DES1), which normally inserts a conserved double bond into the backbone of ceramides. Ablation of DES1 from whole animals or tissue-specific deletion in the liver and/or adipose tissue resolved hepatic steatosis and insulin resistance in mice caused by leptin deficiency or obesogenic diets

Translated text

Key words

Hepatic Steatosis,Lipid Dysregulation

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined